Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico–in vivo extrapolation and physiologically-based pharmacokinetic modeling approach-Reference-Cited by-同舟云学术

Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico–in vivo extrapolation and physiologically-based pharmacokinetic modeling approach

Published:2013-05 Issue:3 Volume:67 Page:203-213
ISSN:1056-8719
Container-title:Journal of Pharmacological and Toxicological Methods
language:en
Short-container-title:Journal of Pharmacological and Toxicological Methods

Author:

Malmborg Jonas,Ploeger Bart A.

Publisher

Elsevier BV

Subject

Pharmacology,Toxicology

Reference50 articles.

1. In silico modeling for the nonlinear absorption kinetics of UK-343,664: A P-gp and CYP3A4 substrate;Abuasal;Molecular Pharmaceutics,2012

2. The effects of pharmaceutical excipients on small intestinal transit;Adkin;British Journal of Clinical Pharmacology,1995

3. Pharmacokinetics of bambuterol during oral administration to asthmatic children;Ahlström;Journal of Clinical Pharmacology,1999

4. A multi-compartmental model generally applicable to physiologically-based pharmacokinetics (Astra-Zeneca, UK);Arundel,1997

5. Stereoselective determination of midodrine and desglymidodrine in culture medium: Application to a biotransformation study employing endophytic fungi;Barth;Electrophoresis,2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perfluoropolyether-Based Gut-Liver-on-a-Chip for the Evaluation of First-Pass Metabolism and Oral Bioavailability of Drugs;ACS Biomaterials Science & Engineering;2024-06-01

2. Enzymatic prodrug degradation in the fasted and fed small intestine: In vitro studies and interindividual variability in human aspirates;International Journal of Pharmaceutics;2024-01

3. IVIVE: Facilitating the Use of In Vitro Toxicity Data in Risk Assessment and Decision Making;Toxics;2022-05-01

4. Bottom-up physiologically based pharmacokinetic modelling for predicting the human pharmacokinetic profiles of the ester prodrug MGS0274 and its active metabolite MGS0008, a metabotropic glutamate 2/3 receptor agonist;Xenobiotica;2022-02-01

5. Recent advances in prodrug-based nanoparticle therapeutics;European Journal of Pharmaceutics and Biopharmaceutics;2021-08